Takeda Announces Exclusive License and Option Agreement with Natrogen for Development of Natura-alpha for Inflammatory Bowel Disease
Baxter Receives FDA Approval of FEIBA [Anti-Inhibitor Coagulant Complex] for Prophylactic Treatment of Hemophilia A&B Patients with Inhibitors
Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol
Alimera Sciences and FDA Enter Into Labeling Discussions for ILUVIEN®, Agree Advisory Committee No Longer Necessary
OvaScience and Intrexon Collaborate to Accelerate Development of OvaScience's OvaTure℠ Technology for Infertility Treatments
Bristol-Myers Squibb Continues Evolution to Specialty BioPharma Through Sale of Its Diabetes Business
Vertex Announces Results of Phase 3 Study of Ivacaftor in People with CF who have the R117H Mutation
The Board of Directors of Algeta ASA unanimously recommends voluntary cash offer from Bayer to acquire the entire issued share capital of Algeta
Amgen Announces Positive Top-Line Results From Phase 3 MENDEL-2 Trial Of Evolocumab (AMG 145) In Patients With High Cholesterol
Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction
THOUSAND OAKS, Calif., Dec.
DARMSTADT, Germany, December 18, 2013 /PRNewswire/ --
ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator for the treatment of COPD in the US
THERAMetrics holding AG (SIX: TMX) and its fully owned subsidiary, Pierrel Research International AG (PRINT), announce €5 Million New Business (Contracts) signed in December 2013
Stans, Switzerland, December 18, 2013 - Ms Maxime Stevens, Group CEO of Pierrel Research International AG announces that, as anticipated in our press release of December 9th, 2013, an additional...